Engineered immune cells take on rare sarcoma in early trial
Disease control
Recruiting now
This study tests a personalized cell therapy called TBI-1301 for people with a rare soft-tissue cancer called synovial sarcoma that has spread or come back. The therapy uses a patient's own immune cells, modified to attack cancer cells with a specific marker (NY-ESO-1). About 5 a…
Phase: PHASE3 • Sponsor: Takara Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC